Login to Your Account

Phase IIs Yield More Biomarkers

MACK Keeps on Trucking, While Deal with Actavis Sweetens Clinic Failure

By Randy Osborne
Staff Writer

Wednesday, November 27, 2013
Oncology partner Sanofi SA likely was not thrilled by the clinical part of the mixed bag of news offered by Merrimack Pharmaceuticals Inc., but a moderate-sized nanoliposomal deal with specialty pharma Actavis plc made Wall Street happy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription